Sugi Predict

Sugi Predict / Compounds / SCHEMBL1442385

SCHEMBL1442385

SCHEMBL1442385

C[C@H]1C[C@H](N)CN1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ MMP2 P08253 1/20 0.39
▸ ANPEP P15144 1/20 0.39
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13495901 1.00 NR1H2 (0.41) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL376475 1.00 NR1H2 (0.41) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL13663627 1.00 NR1H2 (0.41) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL3189177 1.00 NR1H2 (0.41) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL765262 1.00 NR1H2 (0.41) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL29712775 0.85 NR1H2 (0.40) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL31263642 0.85 CHRM2 (0.39) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL30134299 0.85 NR1H2 (0.40) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL16765005 0.85 CHRM2 (0.39) NR1H2TSHRCHRM2CHRM1CHRM3
SCHEMBL16765591 0.85 CHRM2 (0.39) NR1H2TSHRCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
EP-4634186-A1 2,6,9-TRISUBSTITUTED PURINES Astrazeneca AB (SE) 2025-10-22 — — EP disclosed
US-12441744-B2 2,6,9-trisubstituted purines ASTRAZENECA AB 2025-10-14 — — US disclosed
US-20250250230-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-07 — — US disclosed
US-20250197425-A1 2,6,9-TRISUBSTITUTED PURINES ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
EP-4508027-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-02-19 — — EP disclosed
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 — — US disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
EP-4426695-A1 KRAS G12C INHIBITORS Frontier Medicines Corporation (US) 2024-09-11 — — EP disclosed
US-RE41149-E1 Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-23 — — US disclosed
US-6031102-A Optically active pyridonecarboxylic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-02-29 — — US disclosed
EP-0341493-B1 Optically active pyridonecarboxylic acid derivatives DAIICHI SEIYAKU CO (JP) 1999-07-14 — — EP disclosed
US-5767127-A BACTERICIDES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-06-16 — — US disclosed
US-5587386-A BACTERICIDES, MICROBIOCIDES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1996-12-24 — — US disclosed
EP-0659178-A4 CHIRAL QUINOLONE INTERMEDIATES. ABBOTT LAB (US) 1996-03-27 — — EP disclosed
EP-0659178-A1 CHIRAL QUINOLONE INTERMEDIATES ABBOTT LABORATORIES (US) 1995-06-28 — — EP disclosed
WO-1994006766-A1 CHIRAL QUINOLONE INTERMEDIATES ABBOTT LABORATORIES (US) 1994-03-31 — — WO disclosed
US-5252747-A Chiral quinolone intermediates ABBOTT LABORATORIES (US) 1993-10-12 — — US disclosed
EP-0341493-A2 Optically active pyridonecarboxylic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1989-11-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250230-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R NR1H2 90/4885TSHR 337/4885CHRM2 381/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R NR1H2 1215/4885TSHR 24/4885CHRM2 209/4885
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS NR1H2 2175/4885TSHR 3724/4885CHRM2 4870/4885
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 2175/4885TSHR 3724/4885CHRM2 4870/4885
US-12441744-B2 2,6,9-trisubstituted purines CDK2, CDK1, CCNT2 NR1H2 4020/4885TSHR 1474/4885CHRM2 1878/4885
US-20250197425-A1 2,6,9-TRISUBSTITUTED PURINES CDK2, CDK1, CCNT2 NR1H2 4020/4885TSHR 1474/4885CHRM2 1878/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 2175/4885TSHR 3724/4885CHRM2 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.